A
ACELYRIN
Biopharma company focused on providing patients life-changing new treatment options
About ACELYRIN
ACELYRIN is an innovative biopharma company dedicated to developing and commercializing life-changing drug therapies. The company operates in the biopharmaceutical sector, focusing primarily on immunology, where it aims to make a clinically meaningful difference for patients compared to the standard of care. ACELYRIN serves patients who require advanced therapeutic solutions, particularly in areas where existing treatments are inadequate. The company’s business model revolves around investing in, developing, and bringing to market transformative medicines that address unmet medical needs. Revenue is generated through the commercialization of these therapies, including sales and potential partnerships or licensing agreements.
ACELYRIN’s corporate culture is built on the principle of Courageous Caring, emphasizing patient-first initiatives and collaborative efforts. The company is currently advancing several key projects, including the Phase 3 trial of izokibep for hidradenitis suppurativa and a Phase 2b/3 trial for uveitis. These trials are critical milestones that could significantly impact the company’s growth and market presence.
Source: Dealroom company dataNews
Open roles
ACELYRIN in the Los Angeles ecosystem
The ACELYRIN office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Westlake Village BioPartners
Matrix Capital Management
Tybourne Capital Management
OrbiMed
Citadel
venBio Partners
RTW Investments
Marshall Wace
Samsara BioCapital
Decheng Capital- CICowen Healthcare Investments
Series B and later3 investors entered at this stage
Access Biotechnology
Cowen Group
Surveyor Capital
Source: Dealroom Talent Intelligence.
See ACELYRIN on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


